Aimée du Chatinier

659 total citations
9 papers, 147 citations indexed

About

Aimée du Chatinier is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Aimée du Chatinier has authored 9 papers receiving a total of 147 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 3 papers in Molecular Biology and 3 papers in Oncology. Recurrent topics in Aimée du Chatinier's work include Glioma Diagnosis and Treatment (5 papers), Immune cells in cancer (2 papers) and Neuroblastoma Research and Treatments (2 papers). Aimée du Chatinier is often cited by papers focused on Glioma Diagnosis and Treatment (5 papers), Immune cells in cancer (2 papers) and Neuroblastoma Research and Treatments (2 papers). Aimée du Chatinier collaborates with scholars based in Netherlands, United States and Germany. Aimée du Chatinier's co-authors include René Bernards, Cun Wang, Cor Lieftink, Roderick L. Beijersbergen, Guang‐Zhi Jin, Haojie Jin, Wenxin Qin, Dongmei Gao, Hui Wang and Dennis S. Metselaar and has published in prestigious journals such as Gut, Neuro-Oncology and Frontiers in Oncology.

In The Last Decade

Aimée du Chatinier

9 papers receiving 145 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aimée du Chatinier Netherlands 6 98 52 35 30 20 9 147
Kuniyasu Saigusa Japan 5 144 1.5× 53 1.0× 36 1.0× 24 0.8× 28 1.4× 17 231
Sarah G. Injac United States 6 69 0.7× 39 0.8× 62 1.8× 13 0.4× 14 0.7× 11 128
Yuchen Du United States 6 62 0.6× 43 0.8× 54 1.5× 13 0.4× 20 1.0× 14 130
Aniello Federico Germany 9 173 1.8× 70 1.3× 24 0.7× 20 0.7× 44 2.2× 12 224
Nishita Thota Netherlands 4 71 0.7× 80 1.5× 63 1.8× 73 2.4× 8 0.4× 5 192
Domenico Sardella Italy 5 165 1.7× 98 1.9× 14 0.4× 25 0.8× 22 1.1× 5 231
Geraldine Cayanan United States 3 166 1.7× 24 0.5× 28 0.8× 11 0.4× 17 0.8× 3 201
María del Mar Inda Spain 7 154 1.6× 46 0.9× 52 1.5× 17 0.6× 14 0.7× 8 195
Rozario Thomas United States 5 188 1.9× 67 1.3× 61 1.7× 24 0.8× 22 1.1× 6 300
Mariko Nakano‐Okuno United States 7 171 1.7× 46 0.9× 41 1.2× 11 0.4× 15 0.8× 10 234

Countries citing papers authored by Aimée du Chatinier

Since Specialization
Citations

This map shows the geographic impact of Aimée du Chatinier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aimée du Chatinier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aimée du Chatinier more than expected).

Fields of papers citing papers by Aimée du Chatinier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aimée du Chatinier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aimée du Chatinier. The network helps show where Aimée du Chatinier may publish in the future.

Co-authorship network of co-authors of Aimée du Chatinier

This figure shows the co-authorship network connecting the top 25 collaborators of Aimée du Chatinier. A scholar is included among the top collaborators of Aimée du Chatinier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aimée du Chatinier. Aimée du Chatinier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Metselaar, Dennis S., Michaël H. Meel, Aimée du Chatinier, et al.. (2024). Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in atypical teratoid/rhabdoid tumors. Cell Reports Medicine. 5(9). 101700–101700. 3 indexed citations
2.
Metselaar, Dennis S., Aimée du Chatinier, Cristian Ruiz-Moreno, et al.. (2024). DIPG-51. DIFFUSE MIDLINE GLIOMAS HIJACK MYELOID CELL POPULATIONS TO INITIATE AN ANTI-INFLAMMATORY TUMOR IMMUNE MICROENVIRONMENT. Neuro-Oncology. 26(Supplement_4). 0–0. 1 indexed citations
3.
Chatinier, Aimée du, et al.. (2024). DIPG-21. PRECLINICAL ASSESSMENT OF A MULTIMODAL TREATMENT APPROACH WITH GIVINOSTAT, PAXALISIB, AND RADIOTHERAPY FOR DIFFUSE MIDLINE GLIOMA (DMG). Neuro-Oncology. 26(Supplement_4). 0–0. 1 indexed citations
4.
Mulero‐Sánchez, Antonio, Christel Ramirez, Aimée du Chatinier, et al.. (2023). Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma. Molecular Oncology. 17(6). 964–980. 11 indexed citations
5.
Chatinier, Aimée du, et al.. (2023). Microglia in pediatric brain tumors: The missing link to successful immunotherapy. Cell Reports Medicine. 4(11). 101246–101246. 8 indexed citations
6.
Metselaar, Dennis S., Aimée du Chatinier, Michaël H. Meel, et al.. (2022). AURKA and PLK1 inhibition selectively and synergistically block cell cycle progression in diffuse midline glioma. iScience. 25(6). 104398–104398. 18 indexed citations
7.
Chatinier, Aimée du, Michaël H. Meel, Dennis S. Metselaar, et al.. (2022). Generation of immunocompetent syngeneic allograft mouse models for pediatric diffuse midline glioma. Neuro-Oncology Advances. 4(1). vdac079–vdac079. 11 indexed citations
8.
Metselaar, Dennis S., et al.. (2021). Radiosensitization in Pediatric High-Grade Glioma: Targets, Resistance and Developments. Frontiers in Oncology. 11. 662209–662209. 11 indexed citations
9.
Wang, Cun, Hui Wang, Cor Lieftink, et al.. (2019). CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma. Gut. 69(4). 727–736. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kuniyasu Saigusa Breakdown of academic impact, for papers by Sarah G. Injac Breakdown of academic impact, for papers by Yuchen Du Breakdown of academic impact, for papers by Aniello Federico Breakdown of academic impact, for papers by Nishita Thota Breakdown of academic impact, for papers by Domenico Sardella Breakdown of academic impact, for papers by Geraldine Cayanan Breakdown of academic impact, for papers by María del Mar Inda Breakdown of academic impact, for papers by Rozario Thomas Breakdown of academic impact, for papers by Mariko Nakano‐Okuno
Rankless by CCL
2026